EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1
In the last Parallax episode of the year,Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.
This year we had a number of studies that helped clarify our understanding of the world of antiplatelets: First, Ankur and Sukh discuss the take-home messages from HOST-EXAM, a Korean study presented at ACC 2021. They discuss their clinical experiences within the UK and US setting. Next, Sukh talks about the STOPDAPT-2 ACS study, presented at ESC 2021. Sukh interprets the findings in the light of TWILIGHTand summarises his thoughts on the therapy.
2021 was not a great year for physiology: Sukh shares his take on FLOWER-MI, presented at ACC 2021. He offers a deep dive into the data and highlights both the importance of the findings and the limitations of the study.
Next, they discuss RIPCORD 2 from ESC 2021 and finally, Sukh highlights the findings from the FAME 3 trial.
What is the importance of genotype testing in the world of antiplatelets? What are the considerations for clinicians? Should we stop using FFR? How can we incorporate novel findings to patient care? What are the practical considerations that we should take into account when looking at the physiology trials of 2021?
Stay tuned for Part 2 - heart failure and surgical trials coming in 2022.
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read MoreRead Less
Brought to you by Edwards: www.edwardstavr.com
Read MoreRead Less
EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery
In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.
Read More
All Episodes
In this week’s episode Ankur Kalra asks Dr Suzanne J Baron, Director of Interventional Cardiovascular Research at Lahey Hospital & Medical Center: How do we measure the value of a novel technology?
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Read More
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
In this week’s Parallax, host Ankur Kalra is joined by Charles (Chuck) Simonton, Vice President and Chief Medical Officer of Abiomed. Chuck talks about how his father’s leadership and service as a Methodist minister inspired him to become a doctor. He recalls the dawn of interventional cardiology: the birth of angioplasty and stenting. Drawing from his experiences as a trialist who worked with some of the most influential minds, he offers practical tips to young doctors. Finally, Ankur asks Chuck about the Impella device controversy and the recent decision of Abiomed to accelerate their clinical research.
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Read More
How should you start building a research programme? What are Chuck Simonton’s thoughts on the relationship between doctors and the industry? What is Chuck’s message to young cardiologists?
Martha Gulati, Professor of Medicine and the Chief of Cardiology at the University of Arizona joins Ankur Kalra to continue the important conversation on how the cardiovascular community can stand up against sexism.
After the #MedBikini campaign provoked by a misogynistic study that scrutinized female doctors’ social media posts, this episode is about creating a safer environment for female healthcare professionals.
Read More
After the #MedBikini campaign provoked by a misogynistic study that scrutinized female doctors’ social media posts, this episode is about creating a safer environment for female healthcare professionals.
This week’s guest, Prof Roxana Mehran, Professor of Medicine at Mount Sinai and Founding Director of Women as One, is a phenomenon in interventional cardiology. Her pioneering work as clinician, trialist and advocate is well known within the community. In this episode, we learn what makes Roxana tick and what were the odds she had to defy as an immigrant from Iran to fulfil her ‘impossible dream’.
The charity organisation, Women as One is an agent for women and men to be part of medicine that is built on talent, rather than a privilege. Roxana and Ankur discuss the role of mentorship and family-friendly work environment in mending the broken house of cardiology. Roxana talks about the practical tools that are available for women to take the next steps in their career and achieve their goals.
Read More
The charity organisation, Women as One is an agent for women and men to be part of medicine that is built on talent, rather than a privilege. Roxana and Ankur discuss the role of mentorship and family-friendly work environment in mending the broken house of cardiology. Roxana talks about the practical tools that are available for women to take the next steps in their career and achieve their goals.
This week’s guest is Dr Laura Mauri who became Vice President of Global Clinical Research and Analytics at Medtronic in 2018 after an illustrious career in academic medicine at Brigham and Women’s Hospital and Harvard Medical School.
Dr Kalra asks Dr Mauri about early influences and her traineeship with legendary interventionalists, the late Donald Baim and Richard Kuntz. Dr Mauri talks openly about her decision-making process and the importance of selecting your priorities and committing to them. Ankur asks Laura about her decision to go into industry. Laura shares her thoughts on medical innovations and meeting urgent needs with unique perspectives.
What is Dr Mauri’s advice for a young cardiologist? How did she balance research and patient care? What are the questions that helped her decision making? How does Dr Mauri think about innovations in medicine?
Read More
Dr Kalra asks Dr Mauri about early influences and her traineeship with legendary interventionalists, the late Donald Baim and Richard Kuntz. Dr Mauri talks openly about her decision-making process and the importance of selecting your priorities and committing to them. Ankur asks Laura about her decision to go into industry. Laura shares her thoughts on medical innovations and meeting urgent needs with unique perspectives.
What is Dr Mauri’s advice for a young cardiologist? How did she balance research and patient care? What are the questions that helped her decision making? How does Dr Mauri think about innovations in medicine?
In the early days of the Black Lives Matter movement, a group of internal medicine residents posed a question: What can we do about racial disparity within our institution?
Brigham and Women’s Hospital’s Health Equity Committee decided to confront the status quo by asking: How is racism on a structural level present within our walls?
Ankur Kalra’s guests Michelle Morse (Founding Co-Director of EqualHealth and Assistant Professor at Harvard Medical School) and Lauren Eberly (Cardiology Fellow at the University of Pennsylvania) are co-authors of a retrospective study that demonstrated what had previously only been observed: That black or brown heart failure patients ended up in general medicine rather than specialised cardiology services. Following the publication of the study in November 2019, the Health Equity Committee started to roll out anti-racism trainings and to work on objective admission guidelines to mitigate biased behaviours.
Aarti Bhatt (Assistant Professor of Medicine at the University of Minnesota), member of the Minnesota chapter of Campaign Against Racism, talks about their initiative to support projects that have a positive impact on local communities on a global scale.
Read More
Brigham and Women’s Hospital’s Health Equity Committee decided to confront the status quo by asking: How is racism on a structural level present within our walls?
Ankur Kalra’s guests Michelle Morse (Founding Co-Director of EqualHealth and Assistant Professor at Harvard Medical School) and Lauren Eberly (Cardiology Fellow at the University of Pennsylvania) are co-authors of a retrospective study that demonstrated what had previously only been observed: That black or brown heart failure patients ended up in general medicine rather than specialised cardiology services. Following the publication of the study in November 2019, the Health Equity Committee started to roll out anti-racism trainings and to work on objective admission guidelines to mitigate biased behaviours.
Aarti Bhatt (Assistant Professor of Medicine at the University of Minnesota), member of the Minnesota chapter of Campaign Against Racism, talks about their initiative to support projects that have a positive impact on local communities on a global scale.
Heart surgery is not the best option for every patient suffering from structural heart disease. This was recognized by interventional cardiologist Anmar Kanaa’N and cardiac surgeon Joseph Lahorra who decided to unify their skillsets and bring the Structural Heart Program to life. Their vision was to offer patients with heart valve diseases all available options at Cleveland Clinic’s Akron General.
In this week’s Parallax, Dr Kanaa’N, the director of the program, and Dr Lahorra, chairman of the Heart, Vascular & Thoracic Department of Akron General introduce the listeners to the foundations of their program and the paradigm shift brought by TAVR.
Read More
In this week’s Parallax, Dr Kanaa’N, the director of the program, and Dr Lahorra, chairman of the Heart, Vascular & Thoracic Department of Akron General introduce the listeners to the foundations of their program and the paradigm shift brought by TAVR.
The State of Ohio reported its first coronavirus cases on March 9. Prior to that, on February 28, the Cleveland Clinic announced that they are prepared to open 1,000 additional hospital beds if needed. Ohio was one of the states to follow recommendations and intervene quickly.
Ankur Kalra asks Grant W Reed, Director of the Cleveland Clinic’s STEMI program, to reflect on the actions they took and the challenges of delaying cardiovascular procedures in the wake of the coronavirus pandemic. Dr Reed offers insight on the factors that influenced the Cleveland Clinic’s STEMI policy for COVID-19. Ankur and Grant discuss the triage considerations for patients with structural heart disease and the steps the clinic took to protect its healthcare workers.
Read More
Ankur Kalra asks Grant W Reed, Director of the Cleveland Clinic’s STEMI program, to reflect on the actions they took and the challenges of delaying cardiovascular procedures in the wake of the coronavirus pandemic. Dr Reed offers insight on the factors that influenced the Cleveland Clinic’s STEMI policy for COVID-19. Ankur and Grant discuss the triage considerations for patients with structural heart disease and the steps the clinic took to protect its healthcare workers.
Lisa Rosenbaum has been writing extensively about the human face of medicine. Her articles have been widely circulated by publications like The New York Times, The New Yorker and The New England Journal of Medicine.
In this edition of Parallax Dr Kalra asked Dr Rosenbaum about the influences that shaped her choices as a writer and as a healthcare professional. Dr Rosenbaum opens up about her childhood and how she connected to her grandfather through writing and medicine. We learn about Lisa’s first day at medical school and her latest writing project.
Read More
In this edition of Parallax Dr Kalra asked Dr Rosenbaum about the influences that shaped her choices as a writer and as a healthcare professional. Dr Rosenbaum opens up about her childhood and how she connected to her grandfather through writing and medicine. We learn about Lisa’s first day at medical school and her latest writing project.
A week after Jag Singh had tested positive for 2019-nCoV, he became a patient in his hospital’s intensive care unit. This week he joins Ankur Kalra, MD to tell us about his journey as a clinician-scientist.
Jagmeet P Singh, associate chief of the cardiology division at Massachusetts General Hospital and professor of medicine at Harvard Medical School joins Ankur Kalra for a deep conversation about his journey across three continents. Dr Singh talks about the importance of choosing fulfilment over success. We gain more insights on the recent late-breaking trial, MADIT-CHIC focusing on cardiac resynchronization therapy. Ankur asks Jag about his experience of being on the other side of the healthcare system and his enrolment in the since halted remdesivir trial.
Read More
Jagmeet P Singh, associate chief of the cardiology division at Massachusetts General Hospital and professor of medicine at Harvard Medical School joins Ankur Kalra for a deep conversation about his journey across three continents. Dr Singh talks about the importance of choosing fulfilment over success. We gain more insights on the recent late-breaking trial, MADIT-CHIC focusing on cardiac resynchronization therapy. Ankur asks Jag about his experience of being on the other side of the healthcare system and his enrolment in the since halted remdesivir trial.
The first female cardiac surgeon qualified in the 1960’s. Today there are only 4.5% women in cardiology and only 4% in thoracic surgery. Ankur Kalra meets with Dr Kendra Grubb, the first women to be trained at the University of Virginia, US, on cardiothoracic surgery and the 250th board certified women in thoracic surgery.
Her recent post on social media went viral. It was a photo of an all-women surgical team carrying out a complex structural heart procedure. It had over 100,000 views and was seen by people in over 75 different countries. It’s clear from this online reaction, that now is the time for women to be recognised for the work they are doing in medicine.
Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.
Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Her recent post on social media went viral. It was a photo of an all-women surgical team carrying out a complex structural heart procedure. It had over 100,000 views and was seen by people in over 75 different countries. It’s clear from this online reaction, that now is the time for women to be recognised for the work they are doing in medicine.
Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.
Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In our final episode of the year, Ankur has an long conversation with Sukh Nijjer from Imperial College London about the most impactful, exciting and controversial clinical trials of 2019. Sukh and Ankur also discuss how these trials might change practice in the future, and how practice patterns and decisions differ between the US and the UK. In light of an emerging trend of shared decision making between physicians of different specialities and patients with a vast amount of information at their fingertips, Sukh and Ankur examine what tools they use to reconcile the growing data from clinical trials.
Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Recorded before the American Heart Association (AHA) Scientific Sessions 2019, Ankur is joined by Rasha K Al-Lamee, Interventional Cardiologist at Imperial College Healthcare NHS Trust in London and Study Director of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Rasha talks about how she got into academia, the significance of her end-of-training PhD, and what led to the genesis of ORBITA.
Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
In Episode 16, Ankur spoke with Ajay J Kirtane on why he became a cardiologist, how he fell into academic research, and why the cardiology specialty is heavy with people of Indian origin.
Ajay also talks about how he has negotiated between competing priorities in clinical and academic work, and how he manages fatherhood with a busy career. Ahead of the American Heart Association Scientific Sessions 2019, Ajay also shared what he thinks we can expect from the highly anticipate ISCHEMIA trial. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Ajay also talks about how he has negotiated between competing priorities in clinical and academic work, and how he manages fatherhood with a busy career. Ahead of the American Heart Association Scientific Sessions 2019, Ajay also shared what he thinks we can expect from the highly anticipate ISCHEMIA trial. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
How did Gregg from Cleveland, Ohio become Gregg W Stone MD, world-leading interventional cardiologist and clinical trialist? This week, Ankur had the pleasure of speaking to Gregg about his personal and professional journey through the ‘golden years’ of interventional cardiology.
Gregg also shares his tips on how to progress from clinical practice to academic research, and what it takes to be a successful clinical investigator. Finally, Gregg shares with Ankur what personality traits he looks for in mentees and why presenting a final project is not enough. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read More
Gregg also shares his tips on how to progress from clinical practice to academic research, and what it takes to be a successful clinical investigator. Finally, Gregg shares with Ankur what personality traits he looks for in mentees and why presenting a final project is not enough. Submit your question to Ankur via: podcast@radciffe-group.com.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.